Localization and potential role of matrix metalloproteinase-1 and tissue inhibitors of metalloproteinase-1 and-2 in different phases of bronchopulmonary dysplasia

被引:23
|
作者
Dik, WA
De Krijger, RR
Bonekamp, L
Naber, BAE
Zimmermann, LJI
Versnel, MA
机构
[1] Erasmus Univ, Dept Immunol, Sophia Childrens Hosp, Div Neonatol, NL-3000 DR Rotterdam, Netherlands
[2] Erasmus Univ, Dept Pathol, Sophia Childrens Hosp, Div Neonatol, NL-3000 DR Rotterdam, Netherlands
[3] Erasmus Univ, Dept Pediat, Sophia Childrens Hosp, Div Neonatol, NL-3000 DR Rotterdam, Netherlands
[4] Univ Hosp Rotterdam Dijkzigt, Rotterdam, Netherlands
关键词
D O I
10.1203/00006450-200112000-00022
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Bronchopulmonary dysplasia (BPD) can evolve in prematurely born infants who require mechanical ventilation because of hyaline membrane disease (HMD). The development of BPD can be divided in an acute, a regenerative, a transitional and a chronic phase. During these different phases, extensive remodeling of the lung parenchyma with re-epithelialization of the alveoli and formation of fibrosis occurs. Matrix metalloproteinase-1 (MMP-1) is an enzyme that is involved in re-epithelialization processes, and dysregulation of MMP-1 activity contributes to fibrosis. Localization of MMP-1 and its inhibitors, tissue inhibitor of metalloproteinase (TIMP)- 1 and TIMP-2, were investigated in lung tissue obtained from infants who died during different phases of BPD development. In all studied cases (n = 50) type-II pneumocytes were found to be immunoreactive for MMP-1, TEMP-1, and TIMP-2. During the acute and regenerative phase of BPD, type-II pneumocytes re-epithelialize the injured alveoli. This may suggest that MMP-1 and its inhibitors, expressed by type-II pneumocytes, play a role in the reepithelialization process after acute lung injury. Although MMP-1 staining intensity remained constant in type-II pneumocytes during BPD development, TIMP-1 increased during the chronic fibrotic phase. This relative elevation of TIMP-1 compared with MMP-1 is indicative for reduced collagenolytic activity by type-H pneumocytes in chronic BPD and may contribute to fibrosis. Fibrotic foci in chronic BPD contained fibroblasts immunoreactive for MMP- I and TIMP- and -2. This may indicate that decreased collagen turnover by fibroblasts contributes to fibrosis in BPD development.
引用
下载
收藏
页码:761 / 766
页数:6
相关论文
共 50 条
  • [21] Differential expression of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 by human vascular smooth muscle cells
    Kato, S
    Yasukawa, H
    Fujii, T
    Miyagi, M
    Nishi, M
    Morimatsu, M
    Miyamoto, T
    Fox, JC
    ATHEROSCLEROSIS, 1997, 134 (1-2) : 251 - 251
  • [22] Effect of estrogen on the expression of matrix metalloproteinase-1,-3, and tissue inhibitor of metalloproteinase-1 in osteoarthritis chondrocyte.
    Lee, YJ
    Kwon, YE
    Lee, JJ
    Lee, EB
    Song, YW
    ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S61 - S61
  • [23] Crystal structure of the catalytic domain of matrix metalloproteinase-1 in complex with the inhibitory domain of tissue inhibitor of metalloproteinase-1
    Iyer, Shalini
    Wei, Shuo
    Brew, Keith
    Acharya, K. Ravi
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (01) : 364 - 371
  • [24] Influence of hypoxia on the expression of matrix metalloproteinase-1,-3 and tissue inhibitor of metalloproteinase-1 in rheumatoid synovial fibroblasts
    Cha, HS
    Ahn, KS
    Jeon, CH
    Kim, J
    Song, YW
    Koh, EM
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2003, 21 (05) : 593 - 598
  • [25] Tissue inhibitor of matrix metalloproteinase-1 in prostate cancer
    Usher, Pernille Autzen
    Jensen, Helle Lone
    Iversen, Peter
    Mogensen, Peter
    Bartels, Annette
    Brunner, Nils
    APMIS, 2007, 115 (03) : 282 - 282
  • [26] Matrix metalloproteinase-2,-9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension
    Derosa, Giuseppe
    D'Angelo, Angela
    Ciccarelli, Leonardina
    Piccinni, Mario N.
    Pricolo, Fabio
    Salvadeo, Sibilla
    Montagna, Lorenza
    Gravina, Alessia
    Ferrari, Ilaria
    Galli, Simona
    Paniga, Sonia
    Tinelli, Carmine
    Cicero, Arrigo F. G.
    ENDOTHELIUM-JOURNAL OF ENDOTHELIAL CELL RESEARCH, 2006, 13 (03): : 227 - 231
  • [27] Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1 tissue inhibitor in plasma of patients with prostate cancer
    Jung, K
    Nowak, L
    Lein, M
    Priem, F
    Schnorr, D
    Loening, SA
    INTERNATIONAL JOURNAL OF CANCER, 1997, 74 (02) : 220 - 223
  • [28] Concentration of matrix metalloproteinase-1, tissue inhibitor of matrix metalloproteinase-1 and its complex in peritoneal fluid in patients with endometriosis.
    Gogacz, M
    Kotarski, J
    Skorupski, P
    Jakowicki, J
    Rechberger, T
    FERTILITY AND STERILITY, 2002, 77 (02) : S46 - S46
  • [29] Matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1: a possible role in the pathogenesis of endometriosis
    Szamatowicz, J
    Laudanski, P
    Tomaszewska, I
    HUMAN REPRODUCTION, 2002, 17 (02) : 284 - 288
  • [30] Matrix metalloproteinase-2 and-9 and tissue inhibitor of metalloproteinase-1 and-2 in sera and urine of patients with renal carcinoma
    Di Carlo, Angelina
    ONCOLOGY LETTERS, 2014, 7 (03) : 621 - 626